Research programme: VEGF-B protein therapy - Zenyth Therapeutics

Drug Profile

Research programme: VEGF-B protein therapy - Zenyth Therapeutics

Alternative Names: AM-133

Latest Information Update: 19 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zenyth Therapeutics
  • Class Proteins
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 01 Dec 2005 Amrad Corporation is now called Zenyth Therapeutics
  • 06 May 2005 This compound is still in active development
  • 06 May 2005 AM 133 is available for licensing (http://www.amrad.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top